SAN JOSE, Calif.--(BUSINESS WIRE)--OptraSCAN®, the leading end-to-end digital pathology solution provider, today announced that U.S. Patent and Trademark Office (USPTO) has granted a patent to OptraSCAN’s invention, titled ‘Method of Detecting Tissue Area of Interest in Digital Pathology Imaging.’
This newly acquired patent pertains to a software system that can detect tissue’s area of interest and can differentiate between a tumor and a non-tumor cell. OptraSCAN believes that this patent is an important milestone in defending their exclusive artificial intelligence and machine learning based automated image analysis solution; especially created for nuclear & membrane biomarker, immune-oncology, prostate cancer and cytology imaging.
“Innovation in digital pathology is critical for us to improve patient care and OptraSCAN is playing a pivotal role in inventing new technologies in this area. This patent is a strong testament to OptraSCAN’s pioneering efforts in research and development of cancer biomarkers that will help to advance patient care and research worldwide,” said Dr. Jiaoti Huang, Chairman – Medical Advisory Board, OptraSCAN and Chair – Pathology at Duke University.
This patent will pave the way for the recently launched OS-SiA, OptraSCAN’s next-gen AI-enabled digital scanner. OS-SiA is world’s first smart scanner that automatically identifies regions to SCAN and simultaneously analyzes the tissue or cell area being scanned. Founded by Abhi Gholap, OptraSCAN has a patent on slide scanning device granted by USPTO recently.
About OptraSCAN®:
An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN® has developed world’s first ‘On-Demand Digital Pathology’ System; focused on delivering fully integrated, affordable systems & solutions. These serve as the perfect tool for transition from conventional microscopy to Digital Pathology for the effective acquisition of whole slide images, viewing, storing, real time sharing, and reporting via On-Demand or outright purchase model. Follow us on LinkedIn and Twitter